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Abstract
Background: Diabetes diagnosed prior to stroke in young adults is strongly associated with recurrent vascular events. The
relevance of impaired fasting glucose (IFG) and incidence of diabetes after young stroke is unknown. We investigated the
long-term incidence of diabetes after young stroke and evaluated the association of diabetes and impaired fasting glucose
with recurrent vascular events.
Methods: This study was part of the FUTURE study. All consecutive patients between January 1, 1980, and November 1,
2010 with TIA or ischemic stroke, aged 18–50, were recruited. A follow-up assessment was performed in survivors between
November 1, 2009 and January 1, 2012 and included an evaluation for diabetes, fasting venous plasma glucose and
recurrent vascular events. The association of diabetes and IFG with recurrent vascular events was assessed by logistic
regression analysis, adjusted for age, sex and follow-up duration.
Results: 427 survivors without a medical history of diabetes were included in the present analysis (mean follow-up of 10.1
(SD 8.4) years; age 40.3 (SD 7.9) years). The incidence rate of diabetes was 7.9 per 1000 person-years and the prevalence of
IFG was 21.1%. Patients with diabetes and IFG were more likely to have experienced any vascular event than those with
normal fasting glucose values (OR 3.5 (95%CI 1.5–8.4) for diabetes and OR 2.5 (95%CI 1.3–4.8) for IFG).
Conclusions: Diabetes or IFG in young stroke survivors is frequent and is associated with recurrent vascular events. Regular
screening for IFG and diabetes in this population, yields potential for secondary prevention.
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Introduction
Patients, who suffered a stroke at young age, are at high risk of
recurrent vascular events and death [1–3]. Because of the young
age of these patients, the initial stroke as well as possible recurrent
vascular events have a large impact on number of years lost to ill-
health, disability and early death. Previous studies reported that
vascular risk factors are common in these young adults [4,5].
Secondary prevention measures targeting these vascular risk
factors may diminish the risk of recurrent vascular events.
However, risk factors that emerge after a young stroke often may
go undetected in many patients as current protocols and guidelines
only recommend screening of young stroke patients in the acute
phase and only few months thereafter [6].
Risk of recurrent vascular events seems especially high in young
stroke patients with a medical history of diabetes [7]. In both the
general population and in stroke patients over 65 years, also
impaired fasting blood glucose (IFG) or impaired glucose
tolerance, conditions that precede diabetes, have been associated
with an increased risk of vascular events [8,9]. Moreover, more
than half of older stroke patients, who were not previously known
to have diabetes, was diagnosed to have either impaired glucose
tolerance or diabetes three months after stroke [10]. Analogous to
these older stroke patients, young stroke patients without a medical
history of diabetes at the time of their index event may still develop
IFG or incident diabetes after their young stroke as well.
Particularly since regular monitoring of glucose levels after the
acute phase of stroke in young adults without diabetes is seldom
performed. Glucose control in patients with IFG or incident
diabetes could be an important way to reduce risk of recurrent
vascular events [11]. However, the incidence of diabetes and IFG
after stroke in young adults is currently unknown. Moreover, we
are not aware of any study that investigates the association
between impaired fasting blood glucose and recurrent vascular
events in young stroke patients.
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Therefore, we first investigated the incidence of diabetes after a
mean follow-up of 10 years in survivors of a young TIA or
ischemic stroke. Secondly, we investigated whether impaired
fasting blood glucose and diabetes at follow-up were associated
with the occurrence of vascular events during follow-up.
Methods
Patients and study design
This study is a part of the ‘‘Follow-Up of Transient ischemic
attack and stroke patients and Unelucidated Risk factor Evalua-
tion’’ (FUTURE) study, a prospective cohort study of prognosis of
stroke in young adults [2,12]_ENREF_2.The Medical Review
Ethics Committee region Arnhem-Nijmegen approved the study.
In short, the FUTURE study comprised all consecutive patients
aged 18 through 50 years with a TIA, ischemic stroke or
intracerebral hemorrhage admitted to the Radboud university
medical center from January 1, 1980 until November 1, 2010.
Only patients with TIA or ischemic stroke without a medical
history of diabetes, who survived until the follow-up assessment,
were included in the present study. Exclusion criteria were
cerebral venous sinus thrombosis and retinal infarct.
To minimize bias resulting from changing diagnostic tech-
niques, the World Health Organization definitions for TIA and
stroke were used [13,14]. The definition of TIA included a rapidly
evolving focal neurologic deficit, without positive phenomena such
as twitches, jerks or myoclonus, with vascular cause only and
persisting for a period of less than 24 hours. Stroke was defined as
focal neurologic deficit persisting for more than 24 hours. Stroke
was subdivided into ischemic and hemorrhagic stroke, on the basis
of radiological findings.
Patients were identified through a prospective registry of all
patients with young stroke that has been maintained at our centre,
beginning in 1978 [15], with a standardized data collection of
baseline and clinical characteristics, including demographic data,
stroke subtype and vascular risk factors [12]. Assessment of both
the etiology (Trial of Org 10172 in Acute Stroke Treatment
[TOAST] classification) [16] and severity (National Institutes of
Health Stroke Scale [NIHSS]) [17] was performed retrospectively
in all cases on the basis of medical records, because these scales did
not exist when a substantial number of our patients experienced
their index event. In comparison to the original TOAST
classification [18], the presently used classification has an
additional category, ‘‘likely large-artery atherosclerosis’’ [16].
Atherothrombotic stroke is defined as patients with (1) an
ipsilateral internal carotid stenosis .50% (in NASCET criteria),
or (2) an ipsilateral stenosis .50% of another intra/extracranial
artery, or (3) mobile thrombus in the aortic arch. Likely
atherothrombotic stroke is defined as patients with no evidence
of atherothrombotic stroke with (1) an ipsilateral internal carotid
stenosis ,50%, or (2) an ipsilateral stenosis ,50% of another
intra/extracranial artery, or (3) aortic arch plaques .4 mm in
thickness without a mobile component, or (4) a history of
myocardial infarction or coronary revascularization, (5) a history
of documented peripheral arterial disease, or (6) at least two risk
factors for atherosclerotic disease: arterial hypertension (treated or
known blood pressure before stroke .135/85 mm Hg or
hypertensive retinopathy), diabetes mellitus (treated or known
blood fasting glucose .7 mmol/dl), current smoking (or smoking
stopped within the last 6 months), high cholesterol (treated or
known low-density lipoprotein before the stroke .160 mg/dl).
Patients alive were invited for follow-up assessment between
November 1, 2009 and January 1, 2012. Participants provided
written informed consent.
Diabetes and impaired fasting glucose
To answer the first research question, the incidence of diabetes
was the primary outcome measure, either diagnosed during follow-
up or at the follow-up assessment.
The detection of incident diabetes during follow-up was done by
a two step approach. First patients were asked whether diabetes
was diagnosed during the follow-up period, by means of a
standardized structured questionnaire. If so, patients’ general
practitioner was contacted to verify the diagnosis systematically,
and to ascertain information about the plasma glucose level, type
of diagnosed diabetes and initiated treatment.
Secondly, venous plasma samples were taken from all partic-
ipants at the follow-up assessment after overnight fasting to
measure plasma glucose. Whenever glucose was $5.6 mmol/L,
the patient was sent to the general practitioner to obtain a second
fasting venous plasma glucose.
Incident diabetes was defined as: 1) treatment with antidiabetic
medication or a diagnosis of diabetes (confirmed by a physician)
during the follow-up period or 2) two consecutive fasting venous
plasma glucose levels of $7.0 mmol/L at the follow-up assess-
ment.
Regarding the second research question, secondary outcomes
were the prevalence of diabetes or IFG and the occurrence of
vascular events in relation to fasting blood glucose levels at the
follow-up assessment. IFG was only assessed at the follow-up
assessment, defined as a fasting blood glucose of 5.6 mmol/L–
6.9 mmol/L.
Vascular events
Patients were evaluated for recurrent vascular events by means
of a standardized, structured questionnaire [3]. Whenever a
recurrent event was suspected, information retrieved was verified
and adjudicated by physicians from the appropriate specialty
(FEdL, EvD, MvdV).
A composite vascular event was defined as the combination of
stroke (ischemic or hemorrhagic), myocardial infarction, and
cardiovascular procedures (coronary artery bypass grafting,
percutaneous transluminal coronary angioplasty, carotid endar-
terectomy or other peripheral arterial revascularization proce-
dures), whichever occurred first. Separate analyses were done for
stroke and other arterial events.
Statistical analysis
To answer the first research question, the incidence rate of
diabetes was calculated for stroke subtypes. To answer the second
research question, fasting blood glucose values at the follow-up
assessment were categorized into normal fasting blood glucose
(,5.6 mmol/L), impaired fasting blood glucose (5.6 mmol/L–
6.9 mmol/L) and diabetes ($7.0 mmol/L or incident diabetes
during follow-up). Baseline characteristics were compared between
patients without diabetes or impaired fasting glucose and patients
with diabetes or impaired fasting glucose using Student’s t test,
Mann-Whitney U test or chi-square-test whenever appropriate.
Odds ratios were calculated for the association between fasting
blood glucose categories at the follow-up assessment and the
occurrence during follow-up of the composite vascular event, other
arterial events and stroke separately, adjusted for age of the index
stroke, sex, and follow-up duration.
Analyses were done using IBM SPSS Statistics version 20. Two-
sided P values of less than 0.05 were considered to indicate
statistical significance.
Diabetes in Young Stroke and Vascular Events
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Results
427 patients completed follow-up assessment (Figure 1). Baseline
characteristics are presented in table 1. There were no differences
in baseline characteristics between participants and non-partici-
pants (patients lost to follow-up, patients with no venipuncture or
patients who refused), except for history of TIA (3.5% in
participants and 0.7% in nonparticipants).
After a mean follow-up of 10.1 years (SD 8.4), diabetes was
diagnosed in 11 TIA patients (7.1%) and 23 ischemic stroke
patients (8.5%), resulting in an incidence rate per 1000 person
years of 7.9 and 7.8 respectively. Among those without diabetes at
follow-up, 83 patients (21.1%) had an IFG (5.6–6.9 mmol/L) and
310 patients (78.9%) had normal blood glucose values.
Compared with patients without IFG or incident diabetes at the
follow-up assessment, patients with incident diabetes were at
baseline more often older, had a longer mean follow-up duration,
had a likely atherothrombotic stroke, a medical history of
hypertension, a medical history of smoking and a family history
of diabetes (Table 2). Compared with patients without IFG or
incident diabetes at the follow-up assessment, patients with IFG at
the follow-up assessment were at baseline more frequently men,
had a higher age, a longer mean follow-up duration, a likely
atherothrombotic stroke and a medical history of hypertension.
At follow-up, 12 patients with incident diabetes (35.3%) had
experienced any vascular event (composite event) and 7 patients
(20.6%) of them experienced more than one event; 4 patients
(11.8%) had at least one stroke and 10 patients (29.4%) had
experienced at least one other arterial event. Among patients with
IFG at follow-up, 21 patients (25.3%) had experienced any
vascular event and 6 patients (7.2%) of them experienced more
than one event; 10 patients (12.9%) had at least one stroke and 11
patients (13.3%) had experienced at least one other arterial event.
Among patients with normal fasting blood glucose levels at follow-
up, 30 patients (9.7%) had experienced any vascular event and 6
patients (1.9%) of them; 24 patients (7.7%) had experienced at
least one stroke and 8 patients (2.6%) had experienced at least one
other arterial event. In all three fasting blood glucose groups, the
proportion of patients on antiplatelet medication at discharge did
not differ between patients who experienced a recurrent vascular
event compared with patients who did not experience a recurrent
vascular event during follow-up.
Figure 1. Flowchart of the study population.
doi:10.1371/journal.pone.0087171.g001
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After adjusting for age of index stroke, sex and follow-up
duration, patients with diabetes and IFG were more likely to have
experienced any vascular event during follow-up than those with
normal fasting blood glucose values (OR 3.5 (95%CI 1.5–8.4) for
diabetes and OR 2.5 (95%CI 1.3–4.8) for IFG). Risk for the
recurrence of stroke was not different for patients with incident
diabetes and IFG compared with those with normal fasting blood
glucose values (OR 1.2 (95%CI 0.4–4.0) for diabetes and OR 1.4
(95%CI 0.6–3.3) for IFG). Risk of other arterial events was
increased in patients with diabetes and IFG compared with those
with normal fasting blood glucose levels (OR 8.4 (95% CI 2.7–
26.4) for diabetes and (OR 3.6 (95%CI 1.3–9.6) for IFG).
Discussion
We demonstrated that 8% of young stroke survivors developed
diabetes during a mean follow-up of 10 years after stroke, which is
more than two times higher than expected compared with persons
from a Dutch general practitioner registry with similar age and sex
[19]. Moreover, we showed that among those patients without
diabetes at the follow-up assessment, 21% had impaired fasting
blood glucose values. In our study, both patients with diabetes and
patients with IFG at the follow-up assessment were about three
times more likely to experience any vascular event during follow-
up than those with normal fasting blood glucose values.
To our knowledge, our study is the first to evaluate the
incidence of diabetes after stroke in young adults and to study the
association between fasting blood glucose values and recurrent
vascular events. Moreover, our study has the longest follow-up
period reported and one of the largest study populations in the
field of young stroke. Collecting data all in one site allowed us to
collect baseline and follow-up information according to identical
procedures in all patients thereby reducing the risk of information
bias.
Our study has some limitations. First, it may be that not all cases
of young stroke in our catchment area were included in our
cohort, because our cohort is a single-center, hospital-based study,
rather than community-based. Only those patients who sustained
a fatal stroke, who were not admitted to our hospital, would not
have been included in our study. Patients who survive usually visit
a university medical center during the course of their disease. In
addition, there are no restrictions to be admitted to our hospital
and we included all consecutive cases admitted. We therefore
presume that our study population is a representative sample of
Dutch patients with young stroke, although formal data are
lacking to prove this generalizability.
Second, we investigated the association of IFG and diabetes
with recurrent vascular events during follow-up in a cross-sectional
analysis, on average 10 years after the index event in patients that
survived until the follow-up assessment.
Table 1. Baseline characteristics of patients.
Total TIA Ischemic stroke
n (% of total) 427 (100) 156 (36.5) 271 (63.5)
Mean age at event, years (SD) 40.3 (7.9) 41.3 (7.8) 39.9 (7.8)
Male 190 (44.5) 71 (45.5) 119 (43.9)
Median NIHSS at admission (IQR)* 2 (0–6) 0 (0–1) 4 (2–8)
Mean follow-up, years (SD) 10.1 (8.3) 8.9 (8.5) 10.9 (8.2)
TOAST
Atherothrombotic stroke 33 (7.7) 9 (5.8) 24 (8.9)
Likely atherothrombotic stroke 61 (14.3) 27 (17.3) 34 (12.5)
Cardioembolic stroke 44 (10.3) 15 (9.6) 29 (10.7)
Small vessel occlusion 41 (9.6) 7 (4.5) 34 (12.5)
Rare causes 66 (15.5) 16 (10.3) 50 (18.5)
Multiple causes 10 (2.3) 3 (1.9) 7 (2.6)
Unknown cause 172 (40.3) 79 (50.6) 93 (34.3)
Risk factors in medical history
Previous TIA 15 (3.5) 8 (5.1) 7 (2.6)
Previous stroke 6 (1.4) 2 (1.3) 4 (1.5)
Hypertension 101 (23.7) 46 (29.5) 55 (20.3)
Atrial fibrillation 6 (1.4) 2 (1.3) 4 (1.5)
Smoking{ 196 (46.8) 55 (35.9) 141 (53.0)
Excess alcohol consumption` 27 (6.3) 11 (7.1) 16 (5.9)
Family history of diabetes1 175 (41.4) 69 (45.1) 106 (39.3)
Abbreviations: TIA, transient ischemic attack; SD, standard deviation; NIHSS, National Institute of Health Stroke Scale; IQR, interquartile range; TOAST, Trial of Org 10172
in Acute Stroke Treatment.
Data are given as number (percentage) or otherwise stated
*Scores range from 0 to 42 with higher scores on the scale indicating worse stroke severity. 0.5% of NIHSS was missing.
{Smoking was defined as smoking at least 1 cigarette a day in the year prior to the event. 1.9% of data on smoking was missing.
`Excess alcohol consumption was defined as consuming more than 200 grams of pure alcohol per week
1First degree family member. 0.9% of data on family history of diabetes was missing.
doi:10.1371/journal.pone.0087171.t001
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Thus the measurement of blood glucose values is done after a
recurrent event occurred. This may have induced survivor bias.
IFG and diabetes may be associated with the severity of the
recurrent event and as a consequence, patients with IFG and
diabetes may be underrepresented in survivors with recurrent
events, which may have attenuated the association between IFG/
diabetes and recurrent events.
Furthermore, IFG was only measured at the follow-up
assessment, whereas for diabetes also a diagnosis established
during the follow-up period was taken in account. Diabetes that
developed during follow-up might otherwise have been missed at
the follow-up assessment due to initiated treatment.
Third, some patients were lost to follow-up or refused to
participate, which potentially could have resulted in selection bias.
However, non-participants did not differ in baseline characteristic
from participants, making selection bias in this group unlikely.
Fourth, our study has a long inclusion period, during which
diagnostic equipment, acute treatment and secondary prevention
have improved. However, this is an unavoidable feature of a long-
term follow-up study. Furthermore, the long follow-up period
might have resulted in recall bias with respect to vascular events.
However, this probably would have underestimated the associa-
tion between diabetes and recurrent vascular events, since the
incidence of diabetes was strongly related to the number of follow-
up years.
Fifth, secondary prevention might have influenced our results.
In our study about 90% of all patients used secondary preventive
medication at discharge. Consequently the shown risk of recurrent
vascular events might be an underestimation attributable to the
use of this preventive medication. Sixth, as is reflected by the wide
CIs, estimates for some subgroups that contain only a few patients
might be unstable and should therefore be interpreted with
caution.
So far, the only studies reporting on epidemiology of diabetes in
young stroke patients restricted their reports to diabetes diagnosed
prior to stroke. The proportion of patients with a medical history
of diabetes varied widely in these studies, ranging from 2–12%
[7,20,21]. Our observed prevalence of diabetes based on the
medical history of 4.9% is in the middle of this range.
We showed in univariate analysis that incident diabetes after
TIA or ischemic stroke was associated with age, likely athero-
thrombotic stroke and family history of diabetes, which are among
well established risk factors for diabetes in the general population.
In addition, we showed that both patients with diabetes and
patients with IFG were far more likely to have experienced any
arterial event during follow-up than those with normal fasting
blood glucose values. These results suggest an intimate relationship
in young stroke patients between pre-existent vulnerability to
atherosclerosis and incident diabetes, which is an atherogenic risk
factor itself. However, it is also possible that diabetes was already
present but not revealed during the index event.
Table 2. Presence of baseline factors in patients with incident diabetes or impaired fasting glucose at follow-up.
No diabetes or IFG Diabetes p* IFG p{
n (% of total) 310 (72.6) 34 (8.0) 83 (19.4)
Mean age at event, years (SD) 39.2 (8.2) 44.5 (4.5) 0.002 42.8 (6.5) 0.001
Male 123 (39.7) 16 (47.1) 0.41 51 (61.4) ,0.001
Median NIHSS at admission (IQR)` 2 (0–6) 2 (1–4) 0.82 3 (0–6) 0.31
Mean follow-up, years (SD) 8.7 (7.8) 16.7 (8.0) ,0.001 12.6 (8.6) 0.001
TOAST
Atherothrombotic stroke 20 (6.5) 5 (14.7) 0.08 8 (9.6) 0.32
Likely atherothrombotic stroke 30 (9.7) 14 (41.2) ,0.001 17 (20.5) 0.007
Cardioembolic stroke 35 (11.3) 1 (2.9) 0.15 8 (9.6) 0.67
Small vessel occlusion 34 (11.0) 0 0.06 7 (8.4) 0.50
Rare causes 56 (18.1) 1 (2.9) 0.03 9 (10.8) 0.14
Multiple causes 7 (2.3) 1 (2.9) 1.00 2 (2.4) 1.00
Unknown cause 128 (41.3) 12 (35.3) 0.50 32 (38.6) 0.65
Risk factors in medical history
Previous TIA 10 (3.2) 1 (2.9) 1.00 4 (4.8) 0.51
Previous stroke 5 (1.6) 1 (2.9) 1.00 0 0.37
Hypertension 58 (18.7) 14 (41.2) 0.002 29 (34.9) 0.002
Smoking1 133 (43.6) 23 (67.6) 0.008 40 (50.0) 0.31
Excess alcohol consumption|| 19 (6.1) 3 (8.8) 0.71 5 (6.0) 0.97
Family history of diabetes" 124 (40.5) 20 (58.8) 0.04 31 (37.3) 0.60
Abbreviations: IFG, impaired fasting glucose; TIA, transient ischemic attack; SD, standard deviation; NIHSS, National Institute of Health Stroke Scale; IQR, interquartile
range; TOAST, Trial of Org 10172 in Acute Stroke Treatment.
Data are given as number (percentage) or otherwise stated
*p values refer to a comparison between patients with incident diabetes and patients with no IFG or diabetes
{p values refer to a comparison between patients with IFG and patients with no IFG or diabetes
`Scores range from 0 to 42 with higher scores on the scale indicating worse stroke severity. 0.4% of NIHSS was missing.
1Smoking was defined as smoking at least 1 cigarette a day in the year prior to the event. 2.9% of data on smoking was missing.
||Excess alcohol consumption was defined as consuming more than 200 grams of pure alcohol per week
"First degree family member. 1.0% of data on family history of diabetes was missing.
doi:10.1371/journal.pone.0087171.t002
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Incident diabetes or IFG was not associated with recurrent
stroke. An explanation might be that diabetes needs to be present
for many years to be a risk factor for recurrent stroke. This is in
line with a previous study in young adults with ischemic stroke that
showed that among patients with type 1 diabetes, duration of
diabetes was on average 10 years longer in those with recurrent
stroke versus those without recurrent stroke [7]. Another
explanation for the lack of association might be the possibility of
index event bias [22]. In a study investigating recurrence, patients
are included based on the occurrence of the first event that is
similar to the recurrent event. This has an effect on the distribution
of risk factors in this selected population and the association of
these risk factors with the outcome of interest.
The high incidence of diabetes during our long follow-up
period, but also the high proportion of patients with IFG,
emphasizes that young stroke survivors remain vulnerable to the
development of (risk factors for) vascular disease, even decades
after their initial stroke. Active screening for IFG and diabetes
after stroke in young adults may allow for early diagnoses of IFG
and diabetes and thereby provide a therapeutic window to lower
the risk of recurrent vascular events. Similar to the general
population, young stroke patients with a higher age, having other
vascular risk factors or a family history of diabetes, might benefit
the most from active screening.
To conclude, IFG and diabetes after stroke in young patients
may remain unnoticed in many patients. A regular screening for
IFG and diabetes after young stroke, particularly in those with
increasing age, having other vascular risk factors or a family
history of diabetes, yields potential for secondary prevention.
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